SPDR® S&P Pharmaceuticals ETF (XPH)
54.21
+0.85 (+1.59%)
USD |
Mar 01, 10:47
Price Chart
Key Stats
Customize
Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
---|---|---|---|
0.35% | -0.01% | 282.84M | 58319.63 |
Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
0.45% | 31.00% | 30.72M | Upgrade |
Basic Info
Investment Strategy | |
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). |
General | |
Security Type | Exchange-Traded Fund |
Equity Style | Mid Cap/Blend |
Fixed Income Style | -- |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Category Name | Health |
Category Index | S&P 1500 Health Care TR |
Prospectus Objective | Specialty - Health |
Fund Owner Firm Name | SPDR State Street Global Advisors |
Prospectus Benchmark Index | |
S&P Pharms Select Industry TR USD | 100.0% |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Manager Tenure | |
Michael Feehily | 9.26 yrs |
Karl Schneider | 6.26 yrs |
Keith Richardson | 4.08 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
31
30.72M
-4.597B
Category Low
7.682B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of January 31, 2021
Performance Versus Category
As of February 26, 2021. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
Edit comparables
As of February 26, 2021.
Asset Allocation
Top 10 Holdings
Name | % Weight | Price | % Change |
---|---|---|---|
Eli Lilly and Co | 5.06% | 205.71 | 0.40% |
Horizon Therapeutics PLC | 5.00% | 91.37 | 0.51% |
Catalent Inc | 4.78% | 115.85 | 1.88% |
Jazz Pharmaceuticals PLC | 4.72% | 169.52 | 0.88% |
Royalty Pharma PLC Class A | 4.40% | 48.14 | 3.37% |
Elanco Animal Health Inc | 4.36% | 33.49 | 1.92% |
Johnson & Johnson | 4.21% | 160.61 | 1.36% |
Pacira BioSciences Inc | 4.10% | 71.85 | -2.24% |
Bristol-Myers Squibb Company | 4.08% | 61.94 | 0.99% |
Zoetis Inc Class A | 3.94% | 158.23 | 1.93% |
News
Headline
Wire
Time (ET)
SA Breaking News
12/21 15:45
SA Breaking News
09/21 15:14
SA Breaking News
06/22 14:43
SA Breaking News
03/23 16:04
SA Breaking News
12/23 12:07
Basic Info
Investment Strategy | |
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). |
General | |
Security Type | Exchange-Traded Fund |
Equity Style | Mid Cap/Blend |
Fixed Income Style | -- |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Category Name | Health |
Category Index | S&P 1500 Health Care TR |
Prospectus Objective | Specialty - Health |
Fund Owner Firm Name | SPDR State Street Global Advisors |
Prospectus Benchmark Index | |
S&P Pharms Select Industry TR USD | 100.0% |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Manager Tenure | |
Michael Feehily | 9.26 yrs |
Karl Schneider | 6.26 yrs |
Keith Richardson | 4.08 yrs |
Fundamentals
General | |
Distribution Yield | Upgrade |
Dividend Yield TTM (3-1-21) | 0.45% |
30-Day SEC Yield (2-25-21) | Upgrade |
7-Day SEC Yield | -- |
Number of Holdings | Upgrade |
Stock | |
Weighted Average PE Ratio | 25.01 |
Weighted Average Price to Sales Ratio | Upgrade |
Weighted Average Price to Book Ratio | Upgrade |
Weighted Median ROE | Upgrade |
Weighted Median ROA | Upgrade |
Forecasted Dividend Yield | Upgrade |
Forecasted PE Ratio | Upgrade |
Forecasted Price to Sales Ratio | Upgrade |
Forecasted Price to Book Ratio | Upgrade |
As of February 25, 2021
Growth Estimates
Fund Details
Key Dates | |
Inception Date | 6/19/2006 |
Last Annual Report Date | 6/30/2020 |
Last Prospectus Date | 10/31/2020 |
Attributes | |
Enhanced Index Fund | No |
Index Fund |
|
Inverse Fund | No |
Leveraged Fund | No |
Fund of Funds | No |
Currency Hedged Fund | No |
Synthetic Replication Fund | No |
Has Dividend Investment Plan | No |
Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)
SA Breaking News
12/21 15:45
SA Breaking News
09/21 15:14
SA Breaking News
06/22 14:43
SA Breaking News
03/23 16:04
SA Breaking News
12/23 12:07